白云山旗下药品获《药品补充申请批准通知书》

财中社
22 Oct 2024

  财中社10月22日电白云山(600332/00874)发布公告,旗下分公司白云山制药总厂近日获得国家药监局批准的《药品补充申请批准通知书》,涉及脂降宁片和鼻渊片的药品说明书安全性内容变更。

  脂降宁片的补充申请于2024年6月24日递交,销售额在2023年达到605万元。鼻渊片的申请于2024年7月3日递交,销售额为129万元。此次获批将提升上述药品的市场竞争力,但对公司当期业绩无重大影响。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10